Biotech News

Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Salarius Pharmaceuticals (SLRX)Salarius Pharmaceuticals2026-06-25 13:46 ESTCompany update

CAMBRIDGE, Mass. and HOUSTON, April 2, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), announces that on March 31, 2026 the Company received notification from the Nasdaq Stock Market LLC that it has regained compliance with Listing Rule 5550(a)(2), the Minimum

Open original release

Related news

SLRXSalarius Pharmaceuticals2026-06-25 13:46 EST

Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform

SLRXSalarius Pharmaceuticals2026-06-25 13:46 EST

Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement

SLRXSalarius Pharmaceuticals2026-06-25 13:46 EST

Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

SLRXSalarius Pharmaceuticals2026-06-25 13:46 EST

Decoy Therapeutics Joins Webull Corporate Connect Service Platform

SLRXSalarius Pharmaceuticals2026-06-25 13:46 EST

Decoy Therapeutics Announces 1-for-12 Reverse Stock Split

SLRXSalarius Pharmaceuticals2026-06-25 13:46 EST

Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform

SLRXSalarius Pharmaceuticals2026-06-25 13:46 EST

Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026

SLRXSalarius Pharmaceuticals2026-06-25 13:46 EST

Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline

SLRXSalarius Pharmaceuticals2026-06-25 13:46 EST

Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston

NRSNNeuroSense Therapeutics2026-06-25 13:46 EST

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

View all latest news

Salarius Pharmaceuticals

Salarius Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

SLRXSalarius Pharmaceuticals2026-06-26 08:19 EST

Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform

SLRXSalarius Pharmaceuticals2026-06-26 08:19 EST

Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement

SLRXSalarius Pharmaceuticals2026-06-26 08:19 EST

Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

SLRXSalarius Pharmaceuticals2026-06-26 08:19 EST

Decoy Therapeutics Joins Webull Corporate Connect Service Platform

SLRXSalarius Pharmaceuticals2026-06-26 08:19 EST

Decoy Therapeutics Announces 1-for-12 Reverse Stock Split

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States